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Abstract 
Glioblastoma (GBM) is the most common and lethal malignant brain tumor. Current 
treatment involves surgical resection, radiation, and chemotherapy. Temozolomide 
(TMZ) is the only FDA approved systemic chemotherapeutic available and many tumors 
are known to have both extrinsic and intrinsic resistance to the TMZ. Resistance to TMZ 
has generated a pressing need for novel therapies. ONC201, an Akt/ERK dual inhibitor 
has shown promising preliminary results in phase II clinical trials and its potent analog, 
ONC212 is believed to be more clinically efficacious. However, in vitro studies with 
ONC212 are necessary prior to clinical application.  
Normal human astrocytes (NHA) and normal human astrocytes with mutant Ras (NHA 
Ras), along with 6 established glioblastoma human cell lines (U251, U87, U373, LN18, 
LN229, and D54MG) were each evaluated for toxicity with 3 individual drugs (TMZ, 
ONC201, and ONC212) and IC50 values were calculated from toxicity curves. TMZ was 
found to be less effective in cell lines with high MGMT expression (LN18). ONC212 was 
found to be more potent than ONC201 and has the potential to be a possible treatment 
option for GBM. Short-term goals involve repeating the experiment with glioblastoma 
stem cells which better mimic tumor structure with the potential of beginning in vivo 
animal studies and evaluating efficacy and blood brain barrier penetrance of ONC212, 
followed by clinical trials. The ultimate goal remains to develop effective novel therapies 
for patients with GBM.  
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The majority of malignant brain tumors are gliomas, and most gliomas are 
astrocytomas. Glioblastoma (GBM), also known as grade 4 astrocytoma, is the most 
common and lethal malignant brain tumor.1 The current median survival rate of patients 
with GBM is approximately 15 months after diagnosis. Standard of care involves 
surgical resection, radiation, and chemotherapy. However, GBM is diffusely invasive 
and tumors are molecularly heterogenous, making recurrence inevitable and 
development of effective therapeutics difficult.2-4 Additionally, difficulty with central 
nervous system (CNS) penetrance can make developing adequate drug therapies for 
GBM difficult.4 Despite the heterogenous nature of GBM, the current standard of care is 
the same across patients.2, 3 Temozolomide (TMZ), a mono-alkylating agent that 
methylates nitrogenous bases, mainly guanine, is the only FDA approved systemic 
chemotherapeutic available. However, TMZ treatment often leads to harsh off-target 
effects including hemotoxicity and cytotoxicity.2, 5, 6  
Additionally, many tumors also have intrinsic resistance to TMZ or acquire resistance 
over time. A common form of intrinsic resistance in GBM is obtained by overexpression 
of DNA repair protein O6-methylguanine methyltransferase (MGMT), which is capable of 
removing the lesion conferred by TMZ.2, 7, 8 MGMT expression is often governed by the 
methylation of the promoter region of the MGMT gene.9 Furthermore, while the 
mechanisms are not well elucidated, many tumors acquire resistance to TMZ over the 
course of treatment. GBM cells have been shown to induce the expression of MGMT 
protein, decrease Tumor Necrosis Factor-Alpha-Induced Protein 3 (TNFAIP3) 
expression, and upregulation of Signal Transducer and Activator of Transcription 3 
(STAT3) in response to TMZ in order to acquire resistance.7, 10-13 Due to adverse side-
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effects associated with TMZ as well as intrinsic resistance in certain tumor cells, there is 
a pressing need to develop novel and potent therapies that provide targeted treatment 
with little to no detrimental secondary response. 
To this end, ONC201 is a small molecule inhibitor within the imipridone class that is 
currently being tested in phase II clinical trials of patients with GBM.14, 15 ONC201 acts 
by crossing the blood brain barrier and inhibiting the phosphorylation of the 
communicating Akt and ERK pathways, as well as inducing the dephosphorylation of 
Foxo3a. Dephosphorylated Foxo3a translocates into the nucleus and induces 
transcription of the TNF-related apoptosis inducing ligand (TRAIL). ONC201 also 
activates EIF2α which stimulates downstream transcription factors ATF4 and CHOP 
and ultimately upregulates death receptor, DR5. The upregulation of both TRAIL and 
DR5 leads to apoptosis, regardless of p53 status.14-16  
Recent studies utilizing ONC201 in breast cancer cell lines point to the direct targeting 
of mitochondria through suppression of multiple mtDNA genes, independent of TRAIL. 
ONC201 has been shown to target mitochondrial cellular respiration, making cells 
reliant on anaerobic respiration resistant to ONC201.17 However, GBM has specifically 
been shown to heavily rely on glycolysis for energy production.18 This is a potential 
roadblock which may occur when utilizing ONC201 to treat GBM. 
ONC212, a recently-derived potent analog of ONC201, has displayed a favorable 
pharmacokinetic profile in mice against various cancer types, making it an attractive 
potential drug to treat GBM.15, 19, 20 ONC212 has been shown to inhibit both glycolysis 
and oxidative phosphorylation in addition to Akt/ERK inhibition.21 However, further 
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investigation regarding the CNS penetrance, potential molecular targets, and toxicity of 
ONC212 is necessary prior to clinical trials.  
 
Materials and Methods 
Tissue culture 
Normal human astrocytes (NHA) and normal human astrocytes with mutant Ras (NHA 
Ras) cell lines were established and immortalized by expressing HPV oncogenes E6 
and E7 to inhibit the TP53 and Retinoblastoma pathways and hTERT to maintain 
telomere length.22 In addition to NHA and NHA Ras, six established GBM cell lines 
(ECLs) were used: U251, U87, U373, LN18, LN229, and D54MG. Cell lines were 
maintained at 37°C and 5% CO2 in Dulbecco’s Modified Eagle’s Medium (DMEM) with 
10% Fetal Bovine Serum (FBS) and 1% Penicillin-Streptomycin.  
 
Proliferation and cell number optimization 
Cell number optimization and proliferation curves were completed prior to treatment to 
determine plating densities. Optimization was accomplished by plating adherent cells at 
a range of densities in a 96-well tissue culture treated plate and utilizing MTS Cell 
Proliferation Assay Kit (Colorimetric) (197010) once a day from day 0 to day 5 to 
quantify the number cells and calculate doubling times for each cell line. The assay is 
based on the reduction of MTS tetrazolium compound by the metabolic oxidation of 
nicotinamide adenine dinucleotide (NADH) in viable cells to formazan, a media-soluble 
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colored product. MTS was added to cells and plates were incubated for 2 hours at 37°C. 
Absorbance was recorded at a wavelength of 490 nm in order to quantify cell counts.23 
 
Drug treatment 
Once cell number was optimized, adherent cells were plated onto a 96-well tissue 
culture treated plate at the optimized densities to have the same cell counts at time of 
treatment. Cells were treated with one of nine different concentrations of drug (serially 
diluted) or DMSO control the following day. Dimethyl sulfoxide (DMSO) was used as a 
solvent for the drug. Since DMSO is known to be toxic to cells at concentrations greater 
than 1%, it was also incorporated into the serial dilution.24 An equivalent concentration 
of DMSO was used with all cells in order to eliminate its presence as a confounding 
cause of cellular toxicity. MTS Cell Proliferation Assay Kit (Colorimetric) (197010) was, 
again, utilized to quantify the number of viable cells five days following treatment. The 
same procedure involving the MTS Cell Proliferation Assay Kit as conducted in 
proliferation and cell number optimization experiments was used to quantify cell data.23  
 
Statistics 
A triplicate blank was averaged in each plate and subtracted from each well’s 
absorbance to eliminate the absorbance due to the background media color. To 
normalize readings between cell lines, all wells’ absorbances were divided by either the 
average of Day 0 (for proliferation assays) or the DMSO control (for toxicity assays). 
Error bars on proliferation and toxicity curves (panel A in each figure) are standard error 
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calculations. Error bars on dot plots (panel B in each figure) are 95% confidence 
intervals. 
Results 
NHA was used as an approximation of a normal human astrocyte, similar to a negative 
control, while NHA Ras was used as an aggressively oncogenic astrocyte, similar to a 
positive control. NHA and NHA Ras were compared to the 6 ECLs.  
A                                                                              B 
  
Figure 1 (A) Proliferation data over a 5 day time course, measured every 24 hours. 
Relative absorbance at 490 nm was measured by MTS assay and was plotted against 
time to measure cell growth. Bars represent standard error. (B) Doubling time, which 
was calculated using proliferation data by determining the time it takes for cells to 
double. Doubling times were calculated as follows in: NHA (1.054 days), NHA Ras 
(0.726 days), D54MG (1.179 days), LN229 (1.089 days), LN18 (0.903 days), U251 




These doubling times were used to determine the plating cell densities 24 hours prior to 


















Table 1 Proliferation curves were developed after plotting relative absorbance at 490 
nm against time for each of the 8 cell lines (NHA, NHA Ras, U251, U87, U373, LN18, 
LN229, D54MG). Doubling times were calculated from these plots. 
 
A           B 
 9 
 
Figure 2 (A) Each cell line was treated with varying concentrations of TMZ and was 
plotted with relative absorbance of light at 490 nm to obtain toxicity graphs. Bars 
represent standard error. (B) IC50 values were calculated from the TMZ toxicity curves. 
IC50 values were calculated as follows in: NHA (139 µM), NHA Ras (7.77 µM), D54MG 
(5.43 µM), LN229 (10.1 µM), LN18 (654 µM), U251 (58.7 µM), U87 (24.2 µM), U373 
(88.7 µM). Bars represent 95% confidence intervals. 
 
IC50 values for TMZ ranged from minimum of 5.43 µM in D54MG to a maximum of 654 
µM in LN18. NHA had an IC50 of 139 µM and NHA Ras had an IC50 of 7.77 µM.  
 
A           B 
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Figure 3 (A) Each cell line was treated with varying concentrations of ONC201 and was 
plotted with relative absorbance of light at 490 nm to obtain toxicity graphs. Bars 
represent standard error. (B) IC50 values were calculated from the ONC201 toxicity 
curves. IC50 values were calculated as follows in: NHA (1.22 µM), NHA Ras (1.44 µM), 
D54MG (0.56 µM), LN229 (1.33 µM), LN18 (1.31 µM), U251 (1.14 µM), U87 (2.24 µM), 
U373 (0.944 µM). Bars represent 95% confidence intervals. 
 
IC50 values for ONC201 ranged from minimum of 0.056 µM in D54MG to a maximum of 
2.24 µM in U87. NHA had an IC50 of 1.22 µM and NHA Ras had an IC50 of 1.44 µM.  
 
A           B 
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Figure 4 (A) Each cell line was treated with varying concentrations of ONC212 and was 
plotted with relative absorbance of light at 490 nm to obtain toxicity graphs. Bars 
represent standard error. (B) IC50 values were calculated from the ONC212 toxicity 
curves. IC50 values were calculated as follows in: NHA (35.5 nM), NHA Ras (34.9 nM), 
D54MG (22.7 nM), LN229 (38.7 nM), LN18 (34.5 nM), U251 (37.0 nM), U87 (38.6 nM), 
U373 (30.5 nM). Bars represent 95% confidence intervals. 
 
IC50 values for ONC212 ranged from minimum of 22.7 nM in D54MG to a maximum of 
38.7 nM in LN229. U87 had the second highest IC50 of 38.6 nM. NHA had an IC50 of 
35.5 µM and NHA Ras had an IC50 of 34.9 µM. 
IC50 values for NHA, NHA Ras, and ECLs following treatment with TMZ, ONC201, and 














7.77 1.44 34.9 
D54MG 5.43 0.56 22.7 
LN229 10.1 1.33 38.7 
LN18 654 1.31 34.5 
U251 58.7 1.14 37.0 
U87 24.2 2.24 38.6 
U373 88.7 0.944 30.5 
 
Table 2 Toxicity curves were developed after plotting relative absorbance at 490 nm 
against drug concentration for each of the 8 cell lines (NHA, NHA Ras, U251, U87, 
U373, LN18, LN229, D54MG). IC50 values were calculated from these plots. IC50 
values for each cell lines were calculated in response to TMZ, ONC201, and ONC212. 
 
Discussion 
Doubling times vary from 0.726 days to 1.365 days in U373. NHA Ras had a 
significantly short doubling time due to the oncogenic Ras transformation increasing cell 
proliferation (Fig. 1A, 1B, Table 2). TMZ had high IC50 concentrations in comparison to 
ONC201 and ONC212. Cell lines deficient in MGMT (U251, U87, U373, LN229, and 
D54MG) responded better to TMZ compared to cell lines which had high MGMT 
expression (LN18).25-29 NHA Ras responded better to TMZ than NHA due to its short 
doubling time. Since TMZ acts on the genetic level via guanine methylation, it is able to 
cause higher levels of cell death in cells with high proliferation rates (Fig. 2A, 2B). 
ONC201 showed greater efficacy than TMZ in all 8 GBM cell lines and had lower IC50 
values and narrower 95% confidence intervals when compared to TMZ treatments (Fig. 
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2A, 2B, 3A, 3B). These relatively lower IC50 values of ONC201 are clinically promising 
due to the harsh off-target effects associated with TMZ therapy, such as neutropenia, 
thrombocytopenia, nausea, and fatigue.2, 5, 6, 30 A recent phase II clinical trial with 
ONC201 displayed promising results, reporting a median overall survival of 41.6 weeks. 
Two patients continue to receive ONC201 treatment for greater than 12 months. One of 
these patients exhibited regression by 85% in one lesion and 76% in another. The 
second patient remains disease-free following re-resection. The study also reported 
excellent drug tolerance. 31 Due to the high tolerance of ONC201 at 625 mg every 3 
weeks in clinical trials, other studies have begun to explore increased dosage 
frequencies.32 It may be worthwhile to consider ONC212, a potent analog of ONC201, 
as a more effective treatment option.15, 19, 20  
Certain cell lines were more sensitive to treatments than others. D54MG was the most 
sensitive cell line in all treatments. U87 was the least sensitive cell line in ONC201 
treatments and was the second least sensitive cell lines in ONC212 treatment. 
Differences in potency between ONC201 and ONC212 range from 58-fold (U87) to 3.4-
fold (LN229) (Table 2). Both ONC201 and ONC212 had a very narrow range of IC50 
concentrations across cell lines, indicating increased suitability under one dosage, 
which is particularly helpful when treating heterogenous tumor types (Fig. 3A, 3B, 4A, 
4B). Though the exact mechanism of action for ONC212 continues to be evaluated, it is 
believed to operate as a dual Akt/ERK inhibitor, similar to ONC201.15, 19, 20  
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Conclusion and Future Directions 
ONC201 and ONC212 having a narrow range of IC50 concentrations for all 8 cell lines 
can indicate applicability across a wide variety of molecularly variable tumors and the 
capacity to act as improved therapeutics for GBM in comparison to TMZ.  Furthermore, 
utilizing a combined multi-drug treatment plan can aid in accounting for both intrinsic 
and extrinsic drug resistance in molecularly heterogenous tumors. Since ONC212 and 
ONC201 operate as dual Akt/ERK inhibitor, it can be particularly efficacious in tumors 
with high Akt or ERK expression. Inhibiting both Akt and ERK can help quench potential 
response that may occur if only one is inhibited due to Akt and ERK being 
communicating pathways.15, 19, 20 Future directions include performing similar 
experiments with glioblastoma stem cells to better emulate tumor structure due to their 
3-dimensional shape compared to the adherent cell lines which were used. In vivo 
studies in animals and clinical trials of ONC212, continuing ONC201 clinical trials, as 
well as multi-drug therapies to evaluate for potential synergistic effects should also be 
considered. CNS penetrance of ONC212 must also be assessed prior to it being used 
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